.png)
.png)
Renal osteodistrophy occurs due to the factors such as secondary hyperparathyroidism, active vitamin D deficiency, aluminium retention and heparin used during hemodialysis. While renal osteodistrophy was observed in 40 % of cases at chronic hemodialysis in the past, currently this ratio decreased owing to better control of serum phosphate, proper choice of dialysate calcium and administration of prophylactic vitamin D metabolites. In the present study, the effects of different phosphate binders and calcitriol on renal osteodistrophy were investigated. No changes were observed in trabecular bone mineral density (tKMD) at groups who received aluminium hydroxide and calcium carbonate therapy for the first 3 months and after the second 3 months, during which combination of calcium carbonate + calcitriol were administred to the same group, significantly increased tKMD were observed (p<0.05). Consequently, it may be said that changes in tKMD are observed with combined treatments lasting 3 months despite the suggestions made as too longer periods of treatment in literature.